Aethlon Medical Inc (AEMD) 0.1900 $AEMD
Are Exosomes the Next PD-1 in Cancer Research?
ACCESSWIRE - Wed Apr 30, 9:01AM CDT
Whitefish, MT / April 30, 2014 / PD-1, or programmed death protein 1, is certainly a hot button in the field of oncology, with the new immune checkpoint inhibitors pegged by many as part of a wave of new therapies to meet areas of great unmet medical need in cancer treatment. Merck & Co. (NYSE: MRK) has received the coveted FDA "breakthrough" designation for its PD-1 inhibitor lambrolizumab, putting it in a position to vie for the lead with Bristol-Myers Squibb's (NYSE: BMY) antibody nivolumab. Both companies have reported impressive results on their drugs for several cancer types, either as a monotherapy or in combination treatments, including melanoma and non-small cell lung cancer.
Aethlon Medical (AEMD) CEO Note: Cancer Therapy Publication References Aethlon Medical
PR Newswire - Tue Apr 22, 7:01AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Aethlon Medical (AEMD) Note: U.S. Clinical Progression
PR Newswire - Wed Apr 09, 8:25AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Exosomes Shine a Light on Alzheimer's Disease and CTE
ACCESSWIRE - Thu Apr 03, 9:16AM CDT
WHITEFISH, MT / April 3, 2014 Concussions are common in recreational and professional sports with an estimated 1.6 million sustained concussion-related injuries per year in the U.S. alone. Since concussions aren't detectable using X-rays or CT scans, they often go undiagnosed and attempts to prevent them have been difficult. These concussions can lead to far more serious problems like chronic traumatic encephalopathy ("CTE"
- a progressive degenerative disease that can only be diagnosed postmortem.
Aethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target
PR Newswire - Wed Mar 19, 8:29AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.
Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases
ACCESSWIRE - Thu Mar 13, 12:21PM CDT
Whitefish MT / March 13, 2014 / The quest to address long-term neurodegenerative problems associated with traumatic brain injury (TBI) and concussions has received plenty of attention recently, in part because of high profile athletes raising awareness and also because of some breakthrough research by Boston University and the University of California at Los Angeles. With any advancement come arguments on both sides of the debate about the accuracy of statements without extensive clinical research, and the sobering reality is that there still are no reliable treatments for diseases like Alzheimer's disease and chronic traumatic encephalopathy (CTE). All scientific posturing and argumentative rhetoric aside, the fact that companies are making strides in diagnostics and more resources are being devoted to these areas of tremendous unmet medical need are reason for optimism as there are new paths being carved in the evolution of new treatments.
Discovery Could Lead to Major Breakthrough in Alzheimer's Disease and Other Brain Disorders
ACCESSWIRE - Wed Mar 05, 12:30PM CST
Whitefish, MT / March 5, 2014 / Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death. There is reason for optimism, though, with hundreds of organizations working on new treatments and diagnostics, including Neuralstem (NYSE MKT: CUR), Thermo Fisher Scientific (NYSE: TMO) and Aethlon Medical (OTCBB: AEMD).
Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries
PR Newswire - Wed Mar 05, 7:29AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.
Aethlon Medical partners with DaVita Clinical Research to support the feasibility & pivotal study of Aethlon Hemopurifier
M2 - Thu Feb 27, 4:21AM CST
Therapeutic filtration company Aethlon Medical (OTC BB:AEMD) said on Wednesday that it has entered into a non-exclusive agreement to provide clinical management services to support the forthcoming studies of the Aethlon Hemopurifier.
Aethlon Medical Expands Clinical Network Through DaVita Agreement
ACCESSWIRE - Wed Feb 26, 2:01PM CST
Aethlon Medical, Inc. (OTC: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, recently signed an agreement with DaVita Clinical Research (DCR) to support upcoming studies of its Aethlon Hemopurifier®. With experience conducting more than 300 early phase clinical trials through a network of more than 150 investigative physicians, DCR is uniquely positioned to help Aethlon Medical advance its unique Hemopurifier technology. DCR's numerous locations could enable Aethlon's trials to advance more quickly than they would if they were conducted in one clinical site.
Aethlon Medical® Announces Agreement with DaVita Clinical Research®
PR Newswire - Wed Feb 26, 7:03AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.
comScore to Appoint Serge Matta Chief Executive Officer
PR Newswire - Tue Feb 11, 6:00AM CST
comScore, Inc. (NASDAQ: SCOR) today announced that its Board of Directors has appointed Serge Matta as Chief Executive Officer, effective March 1, 2014. Concurrently, Dr. Magid Abraham, comScore's co-founder and current Chief Executive Officer, will become Executive Chairman of the Board of Directors. Gian Fulgoni, comScore's co-founder and current Executive Chairman of the Board of Directors, will become Chairman Emeritus, remaining on the Company's Board of Directors and maintaining his current external-facing industry role on behalf of comScore.
New Sonatype Software Protects The World's Enterprise Software Applications From Security, Compliance, And Licensing Threats
PR Newswire - Wed Jan 29, 1:37PM CST
Sonatype, the software company that enables developers to rapidly build secure software while also eliminating compliance and licensing risk, today released a new version of its Component Lifecycle Management (CLM) software.
Travelocity's Long Weekend Sale Encourages Travelers To Escape The Winter Blues
PR Newswire - Wed Jan 29, 6:19AM CST
It's only January but residents from Dallas to New York City have already been hit with heavy snow, blizzard conditions and freezing temperatures. To combat the winter blues, Travelocity has launched its "Go and Love the Long Weekend" sale, encouraging travelers to make the most of the upcoming Presidents Day holiday with deals on wonderful warm weather getaways.
Alleghany Corporation To Announce Fourth Quarter and Fiscal Year 2013 Results On February 25, 2014
PR Newswire - Fri Jan 24, 11:31AM CST
Alleghany Corporation (NYSE-Y) will release its financial results for the fourth quarter and 2013 fiscal year after the market closes on Tuesday, February 25, 2014. In conjunction with the release, Alleghany will post its financial supplement to the company's web-site at www.alleghany.com.
MD Anderson: Exosomes May Hold Key to Early Detection of Cancer Through Simple Blood Test
ACCESSWIRE - Thu Jan 23, 9:06AM CST
Recent research at The University of Texas MD Anderson Cancer Center suggests that taking exosomes, nano-size extracellular vesicles secreted by nearly all somatic cells and found in body fluids, from the bloodstream could lead to revolutionary diagnostic tests that can identify tumors in the body at a very early stage. Dr. Raghu Kalluri, chairman and professor in MD Anderson's Department of Cancer Biology, explained in a recent news release that scientists now understand that exosomes contain proteins, RNA (ribonucleic acid), MDNA (mitochondrial DNA) and, importantly, large fragments of DNA (deoxyribonucleic acid).
Kids Wish Network Announces Honored Hero Facilities of 2013
PR Newswire - Thu Jan 23, 7:30AM CST
Every year international children's charity Kids Wish Network partners with hundreds of pediatric facilities to recognize kids who overcome life-altering situations with bravery through its Hero of the Month program. Kids Wish Network is excited to announce the Honored Hero Facilities of 2013 that went above and beyond to celebrate these uplifting children.
Whistler Blackcomb Holdings Inc. Announces Timing of Fiscal 2014 First Quarter Financial Results and Conference Call
PR Newswire - Fri Jan 17, 4:00PM CST
Whistler Blackcomb Holdings Inc. (the "Corporation" (TSX:WB) today announced the planned timing of its fiscal 2014 first quarter financial results and conference call.
Global Air Conditioning Systems Market Report 2013 - Scenario, Trends, Industry Analysis, Size, Share and Forecast to 2018
PR Newswire - Wed Jan 08, 1:22PM CST
Dublin - Research and Markets (http://www.researchandmarkets.com/research/9v33pb/air_conditioning) has announced the addition of the "Global Air Conditioning Systems Market Report 2013 - Scenario, Trends, Industry Analysis, Size, Share and Forecast to 2018" report to their offering.
Are Exosomes the Next PD-1 in Cancer Research?
ACCESSWIRE - Wed Apr 30, 9:01AM CDT
Whitefish, MT / April 30, 2014 / PD-1, or programmed death protein 1, is certainly a hot button in the field of oncology, with the new immune checkpoint inhibitors pegged by many as part of a wave of new therapies to meet areas of great unmet medical need in cancer treatment. Merck & Co. (NYSE: MRK) has received the coveted FDA "breakthrough" designation for its PD-1 inhibitor lambrolizumab, putting it in a position to vie for the lead with Bristol-Myers Squibb's (NYSE: BMY) antibody nivolumab. Both companies have reported impressive results on their drugs for several cancer types, either as a monotherapy or in combination treatments, including melanoma and non-small cell lung cancer.
Aethlon Medical (AEMD) CEO Note: Cancer Therapy Publication References Aethlon Medical
PR Newswire - Tue Apr 22, 7:01AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Aethlon Medical (AEMD) Note: U.S. Clinical Progression
PR Newswire - Wed Apr 09, 8:25AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Exosomes Shine a Light on Alzheimer's Disease and CTE
ACCESSWIRE - Thu Apr 03, 9:16AM CDT
WHITEFISH, MT / April 3, 2014 Concussions are common in recreational and professional sports with an estimated 1.6 million sustained concussion-related injuries per year in the U.S. alone. Since concussions aren't detectable using X-rays or CT scans, they often go undiagnosed and attempts to prevent them have been difficult. These concussions can lead to far more serious problems like chronic traumatic encephalopathy ("CTE"
- a progressive degenerative disease that can only be diagnosed postmortem. Aethlon Medical and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target
PR Newswire - Wed Mar 19, 8:29AM CDT
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brain-derived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.
Breakthroughs on the Horizon for CTE and Other Neurodegenerative Diseases
ACCESSWIRE - Thu Mar 13, 12:21PM CDT
Whitefish MT / March 13, 2014 / The quest to address long-term neurodegenerative problems associated with traumatic brain injury (TBI) and concussions has received plenty of attention recently, in part because of high profile athletes raising awareness and also because of some breakthrough research by Boston University and the University of California at Los Angeles. With any advancement come arguments on both sides of the debate about the accuracy of statements without extensive clinical research, and the sobering reality is that there still are no reliable treatments for diseases like Alzheimer's disease and chronic traumatic encephalopathy (CTE). All scientific posturing and argumentative rhetoric aside, the fact that companies are making strides in diagnostics and more resources are being devoted to these areas of tremendous unmet medical need are reason for optimism as there are new paths being carved in the evolution of new treatments.
Discovery Could Lead to Major Breakthrough in Alzheimer's Disease and Other Brain Disorders
ACCESSWIRE - Wed Mar 05, 12:30PM CST
Whitefish, MT / March 5, 2014 / Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death. There is reason for optimism, though, with hundreds of organizations working on new treatments and diagnostics, including Neuralstem (NYSE MKT: CUR), Thermo Fisher Scientific (NYSE: TMO) and Aethlon Medical (OTCBB: AEMD).
Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries
PR Newswire - Wed Mar 05, 7:29AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.
Aethlon Medical partners with DaVita Clinical Research to support the feasibility & pivotal study of Aethlon Hemopurifier
M2 - Thu Feb 27, 4:21AM CST
Therapeutic filtration company Aethlon Medical (OTC BB:AEMD) said on Wednesday that it has entered into a non-exclusive agreement to provide clinical management services to support the forthcoming studies of the Aethlon Hemopurifier.
Aethlon Medical Expands Clinical Network Through DaVita Agreement
ACCESSWIRE - Wed Feb 26, 2:01PM CST
Aethlon Medical, Inc. (OTC: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, recently signed an agreement with DaVita Clinical Research (DCR) to support upcoming studies of its Aethlon Hemopurifier®. With experience conducting more than 300 early phase clinical trials through a network of more than 150 investigative physicians, DCR is uniquely positioned to help Aethlon Medical advance its unique Hemopurifier technology. DCR's numerous locations could enable Aethlon's trials to advance more quickly than they would if they were conducted in one clinical site.
Aethlon Medical® Announces Agreement with DaVita Clinical Research®
PR Newswire - Wed Feb 26, 7:03AM CST
Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.
comScore to Appoint Serge Matta Chief Executive Officer
PR Newswire - Tue Feb 11, 6:00AM CST
comScore, Inc. (NASDAQ: SCOR) today announced that its Board of Directors has appointed Serge Matta as Chief Executive Officer, effective March 1, 2014. Concurrently, Dr. Magid Abraham, comScore's co-founder and current Chief Executive Officer, will become Executive Chairman of the Board of Directors. Gian Fulgoni, comScore's co-founder and current Executive Chairman of the Board of Directors, will become Chairman Emeritus, remaining on the Company's Board of Directors and maintaining his current external-facing industry role on behalf of comScore.
New Sonatype Software Protects The World's Enterprise Software Applications From Security, Compliance, And Licensing Threats
PR Newswire - Wed Jan 29, 1:37PM CST
Sonatype, the software company that enables developers to rapidly build secure software while also eliminating compliance and licensing risk, today released a new version of its Component Lifecycle Management (CLM) software.
Travelocity's Long Weekend Sale Encourages Travelers To Escape The Winter Blues
PR Newswire - Wed Jan 29, 6:19AM CST
It's only January but residents from Dallas to New York City have already been hit with heavy snow, blizzard conditions and freezing temperatures. To combat the winter blues, Travelocity has launched its "Go and Love the Long Weekend" sale, encouraging travelers to make the most of the upcoming Presidents Day holiday with deals on wonderful warm weather getaways.
Alleghany Corporation To Announce Fourth Quarter and Fiscal Year 2013 Results On February 25, 2014
PR Newswire - Fri Jan 24, 11:31AM CST
Alleghany Corporation (NYSE-Y) will release its financial results for the fourth quarter and 2013 fiscal year after the market closes on Tuesday, February 25, 2014. In conjunction with the release, Alleghany will post its financial supplement to the company's web-site at www.alleghany.com.
MD Anderson: Exosomes May Hold Key to Early Detection of Cancer Through Simple Blood Test
ACCESSWIRE - Thu Jan 23, 9:06AM CST
Recent research at The University of Texas MD Anderson Cancer Center suggests that taking exosomes, nano-size extracellular vesicles secreted by nearly all somatic cells and found in body fluids, from the bloodstream could lead to revolutionary diagnostic tests that can identify tumors in the body at a very early stage. Dr. Raghu Kalluri, chairman and professor in MD Anderson's Department of Cancer Biology, explained in a recent news release that scientists now understand that exosomes contain proteins, RNA (ribonucleic acid), MDNA (mitochondrial DNA) and, importantly, large fragments of DNA (deoxyribonucleic acid).
Kids Wish Network Announces Honored Hero Facilities of 2013
PR Newswire - Thu Jan 23, 7:30AM CST
Every year international children's charity Kids Wish Network partners with hundreds of pediatric facilities to recognize kids who overcome life-altering situations with bravery through its Hero of the Month program. Kids Wish Network is excited to announce the Honored Hero Facilities of 2013 that went above and beyond to celebrate these uplifting children.
Whistler Blackcomb Holdings Inc. Announces Timing of Fiscal 2014 First Quarter Financial Results and Conference Call
PR Newswire - Fri Jan 17, 4:00PM CST
Whistler Blackcomb Holdings Inc. (the "Corporation"
(TSX:WB) today announced the planned timing of its fiscal 2014 first quarter financial results and conference call. Global Air Conditioning Systems Market Report 2013 - Scenario, Trends, Industry Analysis, Size, Share and Forecast to 2018
PR Newswire - Wed Jan 08, 1:22PM CST
Dublin - Research and Markets (http://www.researchandmarkets.com/research/9v33pb/air_conditioning) has announced the addition of the "Global Air Conditioning Systems Market Report 2013 - Scenario, Trends, Industry Analysis, Size, Share and Forecast to 2018" report to their offering.
